TCU Place 35 -22nd St. East, Saskatoon, SK    

<< return to program
Dr. John North
Inimex Pharmaceuticals Inc.
Innate Defense Regulators
Tuesday, September 14, 2010
2:30 - 3:00 pm

Abstract: Innate Defense Regulators are “first in class” drugs, now in clinical development. They selectively trigger the body's innate defenses without causing inflammation and offer reduced morbidity and mortality for patients "at-risk" for infection and associated inflammatory disorders.
photo of John North
Dr. North is Chief Operating Officer of Inimex Pharmaceuticals, Inc. He initially trained in the fields of biochemistry & immunology and has been leading drug, vaccine and medical device development programs in industry for over 25 years. He led the early development of Inimex’ Innate Defense Regulator technology, serving as Executive Vice-President of R&D in 2004 and then President & CEO 2005 to 2009. Prior to joining Inimex, Dr. North served as Senior Vice President, Scientific Affairs & CSO of QLT, Inc. in Vancouver. Earlier in his industry career, he worked for 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, becoming Head of Exploratory Development at Ipsen International in the U.K. After receiving a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England, Dr. North carried out post-doctoral studies at the National Institute for Medical Research in London, at the University of California, Berkeley, at the Salk Institute and at Bristol University, England, before becoming Managing Director of Monotech Laboratories Ltd. and a Biotechnology Consultant at PA Technology Ltd. Dr. North has published numerous scientific articles and holds several patents.

Click to view John North's ABIC 2010 presentation